ADMA Biologics, Inc. (ADMA)

adma.jpg
 
Stop, l'aspettiamo più in basso
 
che sfiga è rimbalzata proprio a 2,6 :wall:
 
Ripartiamo dall'ultima trimestrale:

ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019

Strengthened Balance Sheet Through Successful Completion of Underwritten Public Offering

Management to Host Conference Call and Webcast Today at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today reported financial results for the quarter ended March 31, 2020, ADMA’s first fiscal quarter, and provided an overview of recent progress and accomplishments.

...

2020 Outlook and Objectives Update

Commercial launches for BIVIGAM and ASCENIV continue to progress. With in-person field opportunities reduced at medical meetings and customer sites due to “shelter-in-place” orders across the U.S., ADMA has successfully implemented virtual engagement initiatives with key opinion leaders, prescribers and other healthcare professionals to facilitate the ongoing commercial rollouts.
ADMA continues to ramp its production throughput for its commercial products and build inventory to support continued sales growth, market penetration and increase available market supply. While ADMA has not experienced any significant decreases in its plasma collection operations to date, there have been reports that other plasma collection organizations are experiencing more meaningful declines as a result of the COVID-19 pandemic which could lead to potential plasma product supply constraints. ADMA is working diligently to increase its production throughput to potentially offset a portion of any potential supply shortfall the overall IG market may experience due to the COVID-19 pandemic.
Investments in support of our stated supply chain robustness initiatives remain on schedule and within budget and, most notably, the expansion of IG manufacturing capacity continues to be on track:

º Aseptic filling machinery installed, Site Acceptance Testing completed and validation testing underway.
º Successfully manufactured three BIVIGAM conformance batches at an increased plasma pool scale, which has the potential to increase overall plant production capacity by approximately 50% or more.
º Expansion of plasma collection center network continues on track with the commencement of collection center build-outs and the securing of additional locations.

Mr. Grossman continued, “These three substantial objectives and investments, including increased raw material plasma collection, expanded production capacity and aseptic filling capability, are anticipated to change the forward-looking outlook for ADMA in many positive ways, including potentially lowering costs, improving gross margins, providing more flexibility with a reduction to batch production cycle time and ultimately giving ADMA additional end-to-end control previously reserved for only the largest plasma fractionators.”

First Quarter 2020 and Recent Highlights

Achieved first quarter 2020 total revenues of $10.2 million, compared to $3.5 million for the first quarter of 2019, representing a 189% increase.
Strengthened the balance sheet through the successful completion of an underwritten public offering of ADMA’s common stock resulting in net proceeds of $88.7 million to the Company, after deducting underwriting discounts and commissions and other offering expenses.
Strengthened the intellectual property estate protecting ASCENIV. The Company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent extension application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV. The patent extension is expected to publish during the first half of 2020.
Entered into a 5-year manufacturing and supply agreement with a third-party customer to produce and sell plasma-derived intermediate fractions from ADMA’s U.S. Food and Drug Administration (FDA) approved IG manufacturing process. This agreement is expected to add $5-10 million per year in annual revenues for 2020 and 2021, and $10-20 million per year for 2022 through 2024.
Received BioNJ 2020 Innovator Award in recognition of the development and approval of ASCENIV, ADMA’s novel, proprietary immune globulin product.


First Quarter 2020 Financial Results

Total revenues for the quarter ended March 31, 2020 were $10.2 million, compared to $3.5 million for the first quarter ended March 31, 2019, representing an increase of approximately $6.7 million, or 189%. The increase is mainly due to increased sales and production throughput of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2020 totaling $6.4 million, and to a $0.3 million increase in plasma revenues generated by our plasma collection facility in 2020 as compared to the same period of a year ago. Our revenues for the first quarter of 2020 as compared to the first quarter of 2019 were favorably impacted by the FDA approvals of BIVIGAM and ASCENIV on May 9, 2019 and April 1, 2019, respectively, and by the manufacturing and supply agreement we entered into in January 2020 to produce and sell intermediate fractions to a certain customer.

Consolidated net loss for the first quarter of 2020 was $19.2 million, or $(0.26) per basic and diluted share, compared to a consolidated net loss of $13.1 million, or $(0.28) per basic and diluted share, for the first quarter of 2019. The increase in net loss of $6.2 million was primarily due to the increase in cost of product revenue of approximately $7.4 million, which increase is mainly a result of the investment made for the production of BIVIGAM’s conformance lots at an increased plasma pool production scale, which pertains specifically to our planned capacity expansion, as well as other production enhancement initiatives and supply chain investments at the Boca Facility. The increase in net loss during the first quarter of 2020 is also attributable to higher selling, general and administrative expenses of $2.3 million, mainly due to increases in employee compensation expenses in support of our commercialization efforts, increased interest expense of $1.2 million due to our accessing additional debt during the second quarter 2019, along with higher research and development expenses of $0.7 million, primarily related to a study we commenced for ASCENIV to potentially extend its approved and labeled expiration dating, partially offset by the increase in revenues. Included in the net loss for the first quarter of 2020 were non-cash expenses of approximately $1.9 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.

At March 31, 2020, ADMA had cash and cash equivalents of $101.2 million and accounts receivable of $7.1 million, compared to cash and cash equivalents and accounts receivable of $26.8 million and $3.5 million, respectively, at December 31, 2019. ADMA’s net working capital as of March 31, 2020 was $151.6 million, compared to $71.8 million as of December 31, 2019.

In February 2020, ADMA completed an underwritten public offering of 27,025,000 shares of its common stock at a public offering price of $3.50 per share, resulting in net proceeds of $88.7 million
 
Ripartiamo dall'ultima trimestrale:

ADMA Biologics Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress

Achieved First Quarter 2020 Total Revenues of $10.2 Million, a 189% Increase Over First Quarter 2019

Strengthened Balance Sheet Through Successful Completion of Underwritten Public Offering

Management to Host Conference Call and Webcast Today at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., May 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and for the prevention of certain infectious diseases, today reported financial results for the quarter ended March 31, 2020, ADMA’s first fiscal quarter, and provided an overview of recent progress and accomplishments.

...

2020 Outlook and Objectives Update

Commercial launches for BIVIGAM and ASCENIV continue to progress. With in-person field opportunities reduced at medical meetings and customer sites due to “shelter-in-place” orders across the U.S., ADMA has successfully implemented virtual engagement initiatives with key opinion leaders, prescribers and other healthcare professionals to facilitate the ongoing commercial rollouts.
ADMA continues to ramp its production throughput for its commercial products and build inventory to support continued sales growth, market penetration and increase available market supply. While ADMA has not experienced any significant decreases in its plasma collection operations to date, there have been reports that other plasma collection organizations are experiencing more meaningful declines as a result of the COVID-19 pandemic which could lead to potential plasma product supply constraints. ADMA is working diligently to increase its production throughput to potentially offset a portion of any potential supply shortfall the overall IG market may experience due to the COVID-19 pandemic.
Investments in support of our stated supply chain robustness initiatives remain on schedule and within budget and, most notably, the expansion of IG manufacturing capacity continues to be on track:

º Aseptic filling machinery installed, Site Acceptance Testing completed and validation testing underway.
º Successfully manufactured three BIVIGAM conformance batches at an increased plasma pool scale, which has the potential to increase overall plant production capacity by approximately 50% or more.
º Expansion of plasma collection center network continues on track with the commencement of collection center build-outs and the securing of additional locations.

Mr. Grossman continued, “These three substantial objectives and investments, including increased raw material plasma collection, expanded production capacity and aseptic filling capability, are anticipated to change the forward-looking outlook for ADMA in many positive ways, including potentially lowering costs, improving gross margins, providing more flexibility with a reduction to batch production cycle time and ultimately giving ADMA additional end-to-end control previously reserved for only the largest plasma fractionators.”

First Quarter 2020 and Recent Highlights

Achieved first quarter 2020 total revenues of $10.2 million, compared to $3.5 million for the first quarter of 2019, representing a 189% increase.
Strengthened the balance sheet through the successful completion of an underwritten public offering of ADMA’s common stock resulting in net proceeds of $88.7 million to the Company, after deducting underwriting discounts and commissions and other offering expenses.
Strengthened the intellectual property estate protecting ASCENIV. The Company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent extension application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV. The patent extension is expected to publish during the first half of 2020.
Entered into a 5-year manufacturing and supply agreement with a third-party customer to produce and sell plasma-derived intermediate fractions from ADMA’s U.S. Food and Drug Administration (FDA) approved IG manufacturing process. This agreement is expected to add $5-10 million per year in annual revenues for 2020 and 2021, and $10-20 million per year for 2022 through 2024.
Received BioNJ 2020 Innovator Award in recognition of the development and approval of ASCENIV, ADMA’s novel, proprietary immune globulin product.


First Quarter 2020 Financial Results

Total revenues for the quarter ended March 31, 2020 were $10.2 million, compared to $3.5 million for the first quarter ended March 31, 2019, representing an increase of approximately $6.7 million, or 189%. The increase is mainly due to increased sales and production throughput of our immunoglobulin products generated by our Boca Facility manufacturing operations in 2020 totaling $6.4 million, and to a $0.3 million increase in plasma revenues generated by our plasma collection facility in 2020 as compared to the same period of a year ago. Our revenues for the first quarter of 2020 as compared to the first quarter of 2019 were favorably impacted by the FDA approvals of BIVIGAM and ASCENIV on May 9, 2019 and April 1, 2019, respectively, and by the manufacturing and supply agreement we entered into in January 2020 to produce and sell intermediate fractions to a certain customer.

Consolidated net loss for the first quarter of 2020 was $19.2 million, or $(0.26) per basic and diluted share, compared to a consolidated net loss of $13.1 million, or $(0.28) per basic and diluted share, for the first quarter of 2019. The increase in net loss of $6.2 million was primarily due to the increase in cost of product revenue of approximately $7.4 million, which increase is mainly a result of the investment made for the production of BIVIGAM’s conformance lots at an increased plasma pool production scale, which pertains specifically to our planned capacity expansion, as well as other production enhancement initiatives and supply chain investments at the Boca Facility. The increase in net loss during the first quarter of 2020 is also attributable to higher selling, general and administrative expenses of $2.3 million, mainly due to increases in employee compensation expenses in support of our commercialization efforts, increased interest expense of $1.2 million due to our accessing additional debt during the second quarter 2019, along with higher research and development expenses of $0.7 million, primarily related to a study we commenced for ASCENIV to potentially extend its approved and labeled expiration dating, partially offset by the increase in revenues. Included in the net loss for the first quarter of 2020 were non-cash expenses of approximately $1.9 million for stock-based compensation, depreciation and amortization, and non-cash interest expense.

At March 31, 2020, ADMA had cash and cash equivalents of $101.2 million and accounts receivable of $7.1 million, compared to cash and cash equivalents and accounts receivable of $26.8 million and $3.5 million, respectively, at December 31, 2019. ADMA’s net working capital as of March 31, 2020 was $151.6 million, compared to $71.8 million as of December 31, 2019.

In February 2020, ADMA completed an underwritten public offering of 27,025,000 shares of its common stock at a public offering price of $3.50 per share, resulting in net proceeds of $88.7 million

Ciao,
sembra un'ottima trimestrale e con il discorso della terapia del plasma per Covid-19, credo che potrebbe essere una buona opportunità...
Io sono entrato oggi, forse sbagliando, in quanto la sto osservando da settimana scorsa...
 
il MACD starebbe per incrociare al rialzo... chissà :censored:
 

piccolo riepilogo x i neo -Azionisti :D (inteso "anca MI" da oggi)

..
Market Cap_213.36M

Employees _313

Short Float_13.81%

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
 
piccolo riepilogo x i neo -Azionisti :D (inteso "anca MI" da oggi)

..
Market Cap_213.36M

Employees _313

Short Float_13.81%

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Lo sai che non mastico A.T....ma comunque Grazie...
A me basta solo "(inteso "anca MI" da oggi)"
 
piccolo riepilogo x i neo -Azionisti :D (inteso "anca MI" da oggi)

..
Market Cap_213.36M

Employees _313

Short Float_13.81%

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Chav, me ne sono prese un pò a 2,669
 
Chav, me ne sono prese un pò a 2,669

Io sperando in uno spike iniziale, prese in apertura a 2,70...:wall:
Mi raccomando a Voi 2 (Big & Chav), per la mia incolumità...visto che sono il meno esperto...di postare pareri e sensazioni e soprattutto (speriamo il più lontano possibile) alert per via di fuga...
Grazie tante per la vostra disponibilità nel segnalare e commentareOK!
 
Ciao Big,
mi sembra di aver letto da qualche parte che tu utilizzi come piattaforma Directa dLite...
Per il mercato USA la consigli e la maggior parte dei titoli sono tutti negoziabili?
Ti faccio questa domanda perché molti titoli segnalati sia da te che da altri, sulla mia piatta del kaiser, collegata al mio conto on-line, non sono negoziabili e quindi molte volte si perdono delle buone occasioni, perché poi andrebbe fatta richiesta di censimento che fa perdere 2/3 giorni di tempo...
Senza parlare delle commissioni che mi applicano ad eseguito...
Grazie
 
Ciao Big,
mi sembra di aver letto da qualche parte che tu utilizzi come piattaforma Directa dLite...
Per il mercato USA la consigli e la maggior parte dei titoli sono tutti negoziabili?
Ti faccio questa domanda perché molti titoli segnalati sia da te che da altri, sulla mia piatta del kaiser, collegata al mio conto on-line, non sono negoziabili e quindi molte volte si perdono delle buone occasioni, perché poi andrebbe fatta richiesta di censimento che fa perdere 2/3 giorni di tempo...
Senza parlare delle commissioni che mi applicano ad eseguito...
Grazie
non ho grossi problemi in acquisto, ma su diversi titoli non puoi andare short, ad esempio INO non è shortabile, MRNA si
 
consiglio di leggere BENE la trimestrale, e di informarsi : l'azienda produce fondamentalmente derivati del plasma ma NON E' focalizzata sul discorso Covid-19. Collaborano (A livello di "sapere" e "conoscenza") con un pool di altre aziende a dare il know-how a chi invece è direttamente coinvolto nella terapia del plasma per il Covid-19. Non hanno quindi introiti in tal senso, perchè non fanno plasma iperimmune per il Covid-19.
 
Indietro